The COVID-19 (SARS-CoV-2) Antigen Test Kit, developed by Gaobeidian PRISES Biotechnology Co., Ltd, represents a critical advancement in rapid diagnostic solutions for detecting the novel coronavirus. This article provides an in-depth analysis of the product's functionality, technical specifications, applications, and the company's background, while emphasizing its role in modern public health strategies.
The COVID-19 (SARS-CoV-2) Antigen Test Kit utilizes immunochromatography, a widely adopted method for rapid diagnostic testing. This technique relies on the specific interaction between antibodies and antigens to identify the presence of the virus. The test strip comprises two key components:
This method ensures high specificity and sensitivity, as validated by clinical trials and PCR comparisons. The colloidal gold technology enhances the visibility of the test lines, enabling quick and accurate results.
The COVID-19 (SARS-CoV-2) Antigen Test Kit is designed to meet the demands of rapid, accessible, and reliable diagnostics. Its standout features include:
These attributes make it an ideal solution for healthcare providers, laboratories, and individuals seeking quick insights into potential infections.
| Parameter | Details |
|---|---|
| Product Name | COVID-19 (SARS-CoV-2) Antigen Rapid Test Kit |
| Brand | GOLDEN TIME |
| Methodology | Colloidal Gold |
| Specimen Type | Nasal swab, oropharyngeal swab, or nasopharyngeal swab |
| Clinical Sensitivity | 96.33% |
| Clinical Specificity | 99.56% |
| Overall Agreement | 98.79% |
| Packing | 1/5/20 tests/carton (customizable) |
| Reading Time | 10 minutes |
| Service Support | OEM/ODM |
The kit includes the following components, ensuring comprehensive testing capabilities:
The 24-month shelf life under proper storage conditions (2°C–30°C, dry place, no freezing) ensures long-term usability. Once opened, the test card should be used within one hour to maintain accuracy.
The COVID-19 (SARS-CoV-2) Antigen Test Kit is applicable in various scenarios, including:
Its portability and ease of use make it particularly valuable in resource-limited settings where access to advanced laboratories is restricted.
Based in Gaobeidian City, Hebei Province, China, Gaobeidian PRISES Biotechnology Co., Ltd is a leading manufacturer of diagnostic solutions. The company specializes in developing high-quality, cost-effective medical devices to address global health challenges. With a focus on innovation and compliance, PRISES adheres to international standards for quality assurance and safety.
As a OEM/ODM provider, the company collaborates with healthcare organizations worldwide to customize diagnostic tools tailored to specific needs. Their commitment to research and development ensures that products like the COVID-19 Antigen Test Kit meet the evolving demands of public health.
The clinical performance of the COVID-19 (SARS-CoV-2) Antigen Test Kit has been validated through rigorous testing. According to the National Institute of Standards and Technology (NIST), diagnostic tests must demonstrate high sensitivity and specificity to ensure reliable results. The kit's 96.33% clinical sensitivity and 99.56% specificity align with these benchmarks, as noted in NIST's guidelines for rapid antigen tests (NIST, 2023).
Additionally, the colloidal gold-based methodology is recognized for its stability and cost-effectiveness, making it a preferred choice for mass testing initiatives. The NIST emphasizes that such tests should be used in conjunction with clinical evaluation and professional judgment to confirm results, as outlined in their public health guidelines.
The COVID-19 (SARS-CoV-2) Antigen Test Kit by Gaobeidian PRISES Biotechnology Co., Ltd exemplifies the intersection of innovation and accessibility in diagnostic technology. Its rapid results, high accuracy, and user-friendly design position it as a vital tool in the global fight against the pandemic. As NIST underscores, the integration of such technologies into public health strategies is essential for effective disease surveillance and control.
For further information about the product, visit the official product page or explore the company's website.
National Institute of Standards and Technology (NIST). (2023). Guidelines for Rapid Antigen Test Validation. Retrieved from https://www.nist.gov